Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 30, 2025 • 10:51 AM ET

Date/Time Source News Release
04/28/2025 01:38 PM EDT GlobeNewswire Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
04/27/2025 09:00 AM EDT GlobeNewswire UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
04/24/2025 08:00 AM EDT GlobeNewswire Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
04/14/2025 08:41 AM EDT GlobeNewswire UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
04/14/2025 07:30 AM EDT GlobeNewswire Relmada Therapeutics To Present NDV-01 Data at AUA2025
03/27/2025 04:05 PM EDT GlobeNewswire Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
03/26/2025 09:00 AM EDT GlobeNewswire Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
03/25/2025 07:30 AM EDT GlobeNewswire Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
02/06/2025 07:30 AM EST GlobeNewswire Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
12/09/2024 07:30 AM EST GlobeNewswire Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Page

Additional News

As of April 30, 2025 • 10:51 AM ET

Date/Time Source News Release
04/25/2025 02:00 PM EDT PRISM News PRISM Mid-Day Movers: EV Battery Momentum and Weight Loss Financing Lead to Mixed Performance Amidst Market Rally Cooldown
04/23/2025 01:30 PM EDT PRISM News PRISM Mid-Day Movers: Board Shakeups and Biotech Financings Drive Investor Focus
03/27/2025 08:07 PM EDT SeekingAlpha Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development
03/27/2025 08:07 PM EDT SeekingAlpha Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript
03/27/2025 04:56 PM EDT SeekingAlpha Relmada Therapeutics GAAP EPS of -$0.62 beats by $0.08
03/25/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, March 25th, 2025
03/25/2025 05:31 AM EDT US Earnings Reports Expected earnings - Relmada Therapeutics Inc.
03/18/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, March 18th, 2025
03/18/2025 05:31 AM EDT US Earnings Reports Expected earnings - Relmada Therapeutics Inc.
02/06/2025 07:46 AM EST SeekingAlpha Relmada Therapeutics acquires potential therapy for Tourette Syndrome from Asarina Pharma
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.